RXI Pharma (RXII) Reports Q4 Loss of $0.84/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. SPY
2. EYPT
3. TSLA
4. NVDA
5. GNK
6. USO
7. AWK
8. AZN
9. SPCX
10. UNG

Go back to RXI Pharma (RXII) Reports Q4 Loss of $0.84/Share

RXi Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Recent Corporate Highlights

March 26, 2018 4:40 PM EDT

MARLBOROUGH, Mass., March 26, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform today reported its financial results for the fourth quarter and year ended December 31, 2017 and provided a business update.

Logo: http://mma.prnewswire.com/media/594748/RXi_Pharmaceuticals_Corporation_Logo.jpg

"In early 2018, RXi announced a strategic decision to solely focus its development... More